Welcome to BioSeeker Group!

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Additional Information

Published Date Mar 7, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1056
PDF Fact Sheet View Fact Sheet for the report A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market.

    To find out more about A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 companies, from Ceased to Marketed. The report extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer. BioSeeker has applied its unique drug assessment methodology to stratify the colorectal cancer pipeline and discern the level of competition in fine detail.
Major Findings from this report:

* The identified competitive landscape of colorectal cancer drugs is split between the 45% which have unique drug target strategies and the other part which have head-to-head target competing colorectal cancer drugs in 49 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the colorectal cancer drugs in general. Contributing to this fact is heavily utilized drug target strategies like: TOP1, TYMS, CEACAM5, EGFR and TUBB.

* Nine out of ten drug target strategies in Phase II development are new to colorectal cancer drugs and at the same time the greatest numbers of new target strategies are found in Phase II (37%) and Phase I development (21%).

* Small molecules, antibodies and proteins are the dominating compound strategies of colorectal cancer drugs, which represent four fifths of the entire pipeline. Cell therapy based colorectal cancer drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of colorectal cancer drugs.

* The highest number of described drug target strategies of colorectal cancer drugs belongs to Pfizer, Novartis, Hoffmann-La Roche, Eli Lilly and Amgen.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any colorectal cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 20
4.2 List of Tables 20
5 Introduction 28
5.1 The Scope of this Report 28
5.2 Definitions 31
5.3 Abbreviations 31
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 32
6.1 Drug Repositioning in Oncology 32
6.2 Introduction to Targets of Colorectal Cancer Drugs 33
6.2.1 ATPase Activity Targets 40
6.2.2 Auxiliary Transport Protein Activity Targets 41
6.2.3 Carboxy-lyase Activity Targets 42
6.2.4 Catalytic Activity Targets 43
6.2.5 Cell Adhesion Molecule Activity Targets 49
6.2.6 Chaperone Activity Targets 59
6.2.7 Cofactor Binding Targets 62
6.2.8 Complement Activity Targets 64
6.2.9 Cysteine-type Peptidase Activity Targets 67
6.2.10 Cytokine Activity Targets 74
6.2.11 Deacetylase Activity Targets 83
6.2.12 DNA Binding Targets 84
6.2.13 DNA Repair Protein Targets 86
6.2.14 DNA Topoisomerase Activity Targets 87
6.2.15 DNA-directed DNA Polymerase Activity Targets 92
6.2.16 DNA-methyltransferase Activity Targets 99
6.2.17 Extracellular Ligand-gated Ion Channel Activity Targets 100
6.2.18 Extracellular Matrix Structural Constituent Targets 102
6.2.19 G-protein Coupled Receptor Activity Targets 105
6.2.20 Glutathione Transferase Activity Targets 112
6.2.21 Growth Factor Activity Targets 114
6.2.22 Hormone Activity Targets 126
6.2.23 Hydrolase Activity Targets 127
6.2.24 Intracellular Ligand-gated Ion Channel Activity Targets 128
6.2.25 Ion Channel Activity Targets 129
6.2.26 Kinase Activity Targets 130
6.2.27 Kinase Binding Targets 141
6.2.28 Kinase Regulator Activity Targets 143
6.2.29 Ligase Activity Targets 147
6.2.30 Lipid Kinase Activity Targets 151
6.2.31 Lipid Phosphatase Activity Targets 153
6.2.32 Metallopeptidase Activity Targets 155
6.2.33 MHC Class I Receptor Activity Targets 160
6.2.34 Molecular Function Unknown Targets 161
6.2.35 Motor Activity Targets 168
6.2.36 Oxidoreductase Activity Targets 170
6.2.37 Peptidase Activity Targets 176
6.2.38 Peptide Hormone Targets 184
6.2.39 Peroxidase Activity Targets 185
6.2.40 Protease Inhibitor Activity Targets 187
6.2.41 Protein Binding Targets 188
6.2.42 Protein Serine/Threonine Kinase Activity Targets 190
6.2.43 Protein Threonine/Tyrosine Kinase Activity Targets 217
6.2.44 Protein Tyrosine Phosphatase Activity Targets 222
6.2.45 Protein-tyrosine Kinase Activity Targets 231
6.2.46 Receptor Activity Targets 243
6.2.47 Receptor Binding Targets 263
6.2.48 Receptor Signaling Complex Scaffold Activity Targets 270
6.2.49 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 273
6.2.50 RNA Binding Targets 275
6.2.51 RNA-directed DNA Polymerase Activity Targets 276
6.2.52 Serine-type Peptidase Activity Targets 277
6.2.53 Structural Constituent of Cytoskeleton Targets 280
6.2.54 Structural Molecule Activity Targets 282
6.2.55 Transcription Factor Activity Targets 283
6.2.56 Transcription Regulator Activity Targets 304
6.2.57 Transferase Activity Targets 318
6.2.58 Translation Regulator Activity Targets 320
6.2.59 Transmembrane Receptor Activity Targets 322
6.2.60 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 328
6.2.61 Transporter Activity Targets 372
6.2.62 Voltage-gated Ion Channel Activity Targets 374
6.3 The Cancer Genome Project and Targets of Colorectal Cancer Drugs 375
6.3.1 Targets of Colorectal Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 375
6.4 Structure-based Drug Design in Colorectal Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 381
6.5 Target-Target Interactions among Identified Targets of Colorectal Cancer Drugs 385
6.6 The Drug-Target Competitive Landscape 391
6.7 Protein Expression Levels of Identified Targets of Colorectal Cancer Drugs 395
6.8 Pathway Assessment of Colorectal Cancer Drugs 400
6.8.1 Tools for Analysis of Cancer Pathways 401
6.8.2 Pathway Assessment 402
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development 452
7.1 Marketed: New and Unique Drug Target Strategies of Colorectal Cancer Drugs 455
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Colorectal Cancer Drugs 456
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Colorectal Cancer Drugs 457
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Colorectal Cancer Drugs 462
7.5 Preclinical Development: New and Unique Drug Target Strategies of Colorectal Cancer Drugs 467
7.6 No Development Data: New and Unique Drug Target Strategies of Colorectal Cancer Drugs 470
7.7 Drug Target Strategies of Suspended or Terminated Colorectal Cancer Drugs 471
7.8 Target Strategy Development Profiles of Colorectal Cancer Drugs 475
7.8.1 Marketed 480
7.8.2 Phase III 489
7.8.3 Phase II 499
7.8.4 Phase I 578
7.8.5 Preclinical 622
7.8.6 No Data 651
7.8.7 Suspended 652
7.8.8 Ceased 653
7.9 The Competition Through Close Mechanistic Approximation of Colorectal Cancer Drugs 692
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy 700
8.1 Small Molecules 702
8.1.1 Background 702
8.1.2 Target Strategies of Small Molecule Drugs 703
8.2 Peptide & Protein Drugs 716
8.2.1 Background 716
8.2.2 Target Strategies of Peptide and Protein Drugs 717
8.3 Antibodies and Antibody-like Structures 722
8.3.1 Background 722
8.3.2 Target Strategies of Antibody Drugs 722
8.4 Nucleic Acid Therapies 727
8.4.1 Background 727
8.4.2 Target Strategies of Nucleic Acid Drugs 728
8.5 Cell & Gene Therapy 730
8.5.1 Background 730
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 731
8.6 Drug Delivery and Nanotechnology 735
8.6.1 Background 735
8.6.2 Target Strategies of Reformulated Drugs 735
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 738
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator 746
9.1 Competitive Fall-Out Assessment 746
9.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 748
9.3 Abbott 749
9.4 Adherex 751
9.5 Affimed Therapeutics 752
9.6 Alchemia 753
9.7 Alethia Biotherapeutics 755
9.8 Allos Therapeutics 756
9.9 Alnylam 757
9.10 AlphaVax 758
9.11 Alseres Pharmaceuticals 759
9.12 Amgen 760
9.13 Anavex Life Sciences 764
9.14 Antisense Pharma 765
9.15 Apotex 766
9.16 Ariad 767
9.17 ArQule 768
9.18 Array BioPharma 770
9.19 Astellas 772
9.20 AstraZeneca 774
9.21 AVEO 778
9.22 AVI BioPharma 779
9.23 Bayer 780
9.24 Betapharma 783
9.25 BioAlliance Pharma 784
9.26 Biocompatibles 786
9.27 Biogen Idec 788
9.28 BioNumerik 790
9.29 BioVex 792
9.30 Boehringer Ingelheim 793
9.31 Bristol-Myers Squibb 795
9.32 BTG 799
9.33 Can-Fite BioPharma 801
9.34 Cancer Advances 802
9.35 Cancer Research Technology 803
9.36 Celator Pharmaceuticals 805
9.37 Celera 807
9.38 Celgene 808
9.39 Cell Therapeutics 809
9.40 Celldex Therapeutics 811
9.41 Cellmid 812
9.42 Celsion 813
9.43 Celtic Pharma 814
9.44 Center of Molecular Immunology 815
9.45 CG Therapeutics 817
9.46 ChemGenex Pharmaceuticals 818
9.47 Choongwae 819
9.48 Circadian Technologies 820
9.49 Clavis Pharma 821
9.50 Cosmo Pharmaceuticals 822
9.51 CuraGen 823
9.52 CureTech 824
9.53 Curis 825
9.54 Cyclacel 826
9.55 Cylene Pharmaceuticals 827
9.56 Cynvec 828
9.57 CytImmune Sciences 829
9.58 Cytokinetics 830
9.59 Daiichi Sankyo 832
9.60 Dainippon Sumitomo Pharma 836
9.61 Deciphera Pharmaceuticals 837
9.62 Dendreon 839
9.63 Dynavax Technologies 842
9.64 EGEN Inc 843
9.65 Eisai 844
9.66 Eli Lilly 847
9.67 Enkam Pharmaceuticals 852
9.68 EntreMed 853
9.69 Enzon 855
9.70 Epeius Biotechnologies 857
9.71 EpiCept 858
9.72 Etubics 859
9.73 Exelixis 860
9.74 FasTrack Pharmaceuticals 864
9.75 Genmab 865
9.76 Genta 867
9.77 GenVec 868
9.78 Genzyme 869
9.79 Gilead Sciences 871
9.80 GlaxoSmithKline 872
9.81 GlycoGenesys 876
9.82 Gradalis 877
9.83 Green Cross 878
9.84 Heidelberg Pharma 879
9.85 Hoffmann-La Roche 880
9.86 Human Genome Sciences 886
9.87 Idera Pharmaceuticals 888
9.88 IkerChem 889
9.89 Immunocore 890
9.90 Immunomedics 891
9.91 Incyte Corporation 894
9.92 InNexus Biotechnology 895
9.93 Inovio 896
9.94 Insys Therapeutics 897
9.95 Introgen Therapeutics 899
9.96 Ipsen 900
9.97 ISA Pharmaceuticals 902
9.98 Ivy Medical Chemicals 903
9.99 Jennerex Biotherapeutics 904
9.100 Johnson & Johnson 905
9.101 Kiadis 907
9.102 Kyowa Hakko Kirin 908
9.103 Labopharm 911
9.104 Leo 913
9.105 Lorus Therapeutics 914
9.106 MacroGenics 916
9.107 Meda 917
9.108 MediGene 918
9.109 Merck & Co 919
9.110 Merck KGaA 921
9.111 Merrimack 924
9.112 Mersana Therapeutics 926
9.113 MethylGene 928
9.114 Micromet 929
9.115 Mitsubishi Tanabe Pharma 931
9.116 MolMed 933
9.117 Mologen 934
9.118 Nektar Therapeutics 936
9.119 Nerviano Medical Sciences 938
9.120 NicOx 940
9.121 Nippon Kayaku 942
9.122 Non-industrial Sources 944
9.123 Novartis 946
9.124 Nycomed Pharma 951
9.125 OncoGenex Pharmaceuticals 952
9.126 OncoMed 953
9.127 Onconova 954
9.128 Oncothyreon 955
9.129 Oncozyme Pharma 957
9.130 Onyvax 958
9.131 Orca Therapeutics 959
9.132 Orchestra Therapeutics 960
9.133 Oxford BioMedica 961
9.134 OXiGENE 962
9.135 PanaGin 963
9.136 Pfizer 964
9.137 Pharmaclon 970
9.138 PharmaGap 971
9.139 PharmaMar 972
9.140 Pharmexa 973
9.141 Philogen 975
9.142 Pierre Fabre 977
9.143 Plexxikon 978
9.144 POZEN 980
9.145 Pro-Pharmaceuticals 982
9.146 Protherics 984
9.147 Receptor BioLogix 985
9.148 Regeneron 986
9.149 Rigel 987
9.150 Sanofi-Aventis 989
9.151 Santaris Pharma 990
9.152 Sareum 991
9.153 Shire 993
9.154 Sigma-Tau 994
9.155 Simcere Pharmaceuticals 996
9.156 Spirogen 997
9.157 SRI International 998
9.158 SuperGen 999
9.159 Supratek Pharma 1001
9.160 SynDevRx 1003
9.161 Synta Pharmaceuticals 1004
9.162 Taiho 1005
9.163 Takeda 1008
9.164 Talon Therapeutics 1010
9.165 Targepeutics 1011
9.166 Tau Therapeutics 1012
9.167 Taxolog 1014
9.168 Telik 1015
9.169 Thallion Pharmaceuticals 1016
9.170 The Genetics Company 1017
9.171 Therion Biologics 1019
9.172 ThromboGenics 1021
9.173 Titan Pharmaceuticals 1022
9.174 TopoTarget 1024
9.175 Transgene 1026
9.176 Trion Pharma 1027
9.177 Vertex Pharmaceuticals 1028
9.178 Vical 1029
9.179 VioQuest Pharmaceuticals 1031
9.180 Viralytics 1033
9.181 Wilex 1034
9.182 Wyeth 1035
9.183 Xerion 1036
9.184 Yakult Honsha 1037
9.185 YM BioSciences 1039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050

List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Colorectal Cancer Drugs 390
Figure 2: The Drug-Target Competitive Landscape of Colorectal Cancer Drugs - Large Cluster 392
Figure 3: The Drug-Target Competitive Landscape Colorectal Cancer Drugs - Smaller Clusters 393
Figure 4: Head-to-Head Targeting Competitive Landscape of Colorectal Cancer Drugs 394
Figure 5: Distribution of Compound Strategies among Colorectal Cancer Drugs 738
Figure 6: Primary Sub-cellular Localization of Drug Targets 739

List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Colorectal Cancer Drug Pipeline by Stage of Development 28
Table 3: Head to Head Target Competition among Colorectal Cancer Drugs 28
Table 4: Overview of Drug Target Strategy Themes 33
Table 5: Terminally Ceased and Suspended Targets of Colorectal Cancer Drugs 34
Table 6: Official Gene Name to Target Profle 35
Table 7: Targets of Colorectal Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 376
Table 8: Identity of Colorectal Cancer Drug Targets with Available Biological Structures 381
Table 9: Number of Target-Target Interactions among Targets of Colorectal Cancer Drugs 385
Table 10: Available Protein Expression Profiles of Colorectal Cancer Drugs Targets 395
Table 11: Pathway Summary 402
Table 12: Drug Targets without any Identified Assigned Pathways 402
Table 13: Pathway Profiles According to BioCarta of Colorectal Cancer Drug Targets 404
Table 14: Pathway Profiles According to KEGG of Colorectal Cancer Drug Targets 424
Table 15: Pathway Profiles According to NetPath of Colorectal Cancer Drug Targets 447
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 452
Table 17: Top Competitive Target Strategies of Colorectal Cancer Drugs 453
Table 18: New and Unique Target Strategies of Marketed Colorectal Cancer Drugs 455
Table 19: The Competition Through Close Mechanistic Approximation Between Colorectal Cancer Drugs being Marketed 455
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Colorectal Cancer Drugs 456
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Colorectal Cancer Drugs 456
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Colorectal Cancer Drugs 457
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Colorectal Cancer Drugs 460
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Colorectal Cancer Drugs 462
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Colorectal Cancer Drugs 465
Table 26: New and Unique Target Strategies in Preclinical Development of Colorectal Cancer Drugs 467
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Colorectal Cancer Drugs 469
Table 28: New and Unique Target Strategies in Unknown Developmental Stage of Colorectal Cancer Drugs 470
Table 29: Target Strategies of Suspended and Terminated Colorectal Cancer Drugs 471
Table 30: Connecting Target Strategy with Its Profile Identification Number 475
Table 31: The Competition Through Close Mechanistic Approximation Among Colorectal Cancer Drugs 692
Table 32: Overview of Compound Strategy Competition Among Colorectal Cancer Drugs 701
Table 33: Overview of the Competitive Landscape of Small Molecule Based Colorectal Cancer Drugs 703
Table 34: Competitive Comparison of Target Strategies of Small Molecule Colorectal Cancer Drugs 704
Table 35: Pursued Target Strategies of Small Molecule Drugs Based Colorectal Cancer Drugs 709
Table 36: Overview of the Competitive Landscape of Peptide Based Colorectal Cancer Drugs 717
Table 37: Pursued Target Strategies of Peptide Based Colorectal Cancer Drugs 718
Table 38: Overview of the Competitive Landscape of Protein Based Colorectal Cancer Drugs 719
Table 39: Competitive Comparison of Target Strategies of Protein Based Colorectal Cancer Drugs 720
Table 40: Pursued Target Strategies of Protein Based Colorectal Cancer Drugs 720
Table 41: Overview of the Competitive Landscape of Antibody Based Colorectal Cancer Drugs 722
Table 42: Competitive Comparison of Target Strategies of Antibody Based Colorectal Cancer Drugs 723
Table 43: Pursued Target Strategies of Antibody Based Colorectal Cancer Drugs 724
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Colorectal Cancer Drugs 728
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Colorectal Cancer Drugs 729
Table 46: Pursued Target Strategies of Nucleic Acid Based Colorectal Cancer Drugs 729
Table 47: Potential Forms of Cell Therapy 730
Table 48: Vectors in Gene Therapy 731
Table 49: Overview of the Competitive Landscape of Cell Therapy Based Colorectal Cancer Drugs 731
Table 50: Pursued Target Strategies of Cell Therapy Based Colorectal Cancer Drugs 732
Table 51: Overview of the Competitive Landscape of Gene Therapy Based Colorectal Cancer Drugs 733
Table 52: Competitive Comparison of Target Strategies of Gene Therapy Based Colorectal Cancer Drugs 734
Table 53: Pursued Target Strategies of Gene Therapy Based Colorectal Cancer Drugs 734
Table 54:Overview of the Competitive Landscape of Reformulated Colorectal Cancer Drugs 735
Table 55: Competitive Comparison of Target Strategies of Reformulated Colorectal Cancer Drugs 736
Table 56: Pursued Target Strategies of Reformulated Colorectal Cancer Drugs 737
Table 57: Compound Strategies based on Sub-Cellular Localization of Colorectal Cancer Drug Targets 739
Table 58: Example of a Competitive Fall-Out Table (Targeting EGFR) 747
Table 59: Summary Table of Corporate Changes in the Competitive Landscape of Colorectal Cancer Drug Development 748
Table 60: Abbott’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 749
Table 61: Adherex’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 751
Table 62: Affimed Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 752
Table 63: Alchemia’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 753
Table 64: Alethia Biotherapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 755
Table 65: Allos Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 756
Table 66: Alnylam’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 757
Table 67: AlphaVax’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 758
Table 68: Alseres Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 759
Table 69: Amgen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 760
Table 70: Anavex Life Sciences’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 764
Table 71: Antisense Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 765
Table 72: Apotex’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 766
Table 73: Ariad’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 767
Table 74: ArQule’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 768
Table 75: Array BioPharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 770
Table 76: Astellas’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 772
Table 77: AstraZeneca’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 774
Table 78: AVEO’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 778
Table 79: AVI BioPharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 779
Table 80: Bayer’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 780
Table 81: Betapharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 783
Table 82: BioAlliance Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 784
Table 83: Biocompatibles’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 786
Table 84: Biogen Idec’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 788
Table 85: BioNumerik’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 790
Table 86: BioVex’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 792
Table 87: Boehringer Ingelheim’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 793
Table 88: Bristol-Myers Squibb’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 795
Table 89: BTG’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 799
Table 90: Can-Fite BioPharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 801
Table 91: Cancer Advances’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 802
Table 92: Cancer Research Technology’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 803
Table 93: Celator Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 805
Table 94: Celera’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 807
Table 95: Celgene’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 808
Table 96: Cell Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 809
Table 97: Celldex Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 811
Table 98: Cellmid’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 812
Table 99: Celsion’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 813
Table 100: Celtic Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 814
Table 101: Center of Molecular Immunology’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 815
Table 102: CG Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 817
Table 103: ChemGenex Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 818
Table 104: Choongwae’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 819
Table 105: Circadian Technologies’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 820
Table 106: Clavis Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 821
Table 107: Cosmo Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 822
Table 108: CuraGen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 823
Table 109: CureTech’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 824
Table 110: Curis’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 825
Table 111: Cyclacel’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 826
Table 112: Cylene Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 827
Table 113: Cynvec’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 828
Table 114: CytImmune Sciences’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 829
Table 115: Cytokinetics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 830
Table 116: Daiichi Sankyo’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 832
Table 117: Dainippon Sumitomo Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 836
Table 118: Deciphera Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 837
Table 119: Dendreon’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 839
Table 120: Dynavax Technologies’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 842
Table 121: EGEN Inc’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 843
Table 122: Eisai’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 844
Table 123: Eli Lilly’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 847
Table 124: Enkam Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 852
Table 125: EntreMed’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 853
Table 126: Enzon’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 855
Table 127: Epeius Biotechnologies’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 857
Table 128: EpiCept’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 858
Table 129: Etubics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 859
Table 130: Exelixis’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 860
Table 131: FasTrack Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 864
Table 132: Genmab’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 865
Table 133: Genta’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 867
Table 134: GenVec’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 868
Table 135: Genzyme’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 869
Table 136: Gilead Sciences’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 871
Table 137: GlaxoSmithKline’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 872
Table 138: GlycoGenesys’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 876
Table 139: Gradalis’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 877
Table 140: Green Cross’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 878
Table 141: Heidelberg Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 879
Table 142: Hoffmann-La Roche’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 880
Table 143: Human Genome Sciences’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 886
Table 144: Idera Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 888
Table 145: IkerChem’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 889
Table 146: Immunocore’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 890
Table 147: Immunomedics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 891
Table 148: Incyte Corporation’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 894
Table 149: InNexus Biotechnology’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 895
Table 150: Inovio’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 896
Table 151: Insys Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 897
Table 152: Introgen Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 899
Table 153: Ipsen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 900
Table 154: ISA Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 902
Table 155: Ivy Medical Chemicals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 903
Table 156: Jennerex Biotherapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 904
Table 157: Johnson & Johnson’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 905
Table 158: Kiadis’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 907
Table 159: Kyowa Hakko Kirin’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 908
Table 160: Labopharm’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 911
Table 161: Leo’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 913
Table 162: Lorus Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 914
Table 163: MacroGenics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 916
Table 164: Meda’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 917
Table 165: MediGene’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 918
Table 166: Merck & Co’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 919
Table 167: Merck KGaA’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 921
Table 168: Merrimack’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 924
Table 169: Mersana Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 926
Table 170: MethylGene’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 928
Table 171: Micromet’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 929
Table 172: Mitsubishi Tanabe Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 931
Table 173: MolMed’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 933
Table 174: Mologen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 934
Table 175: Nektar Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 936
Table 176: Nerviano Medical Sciences’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 938
Table 177: NicOx’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 940
Table 178: Nippon Kayaku’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 942
Table 179: Non-industrial source’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 944
Table 180: Novartis’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 946
Table 181: Nycomed Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 951
Table 182: OncoGenex Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 952
Table 183: OncoMed’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 953
Table 184: Onconova’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 954
Table 185: Oncothyreon’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 955
Table 186: Oncozyme Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 957
Table 187: Onyvax’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 958
Table 188: Orca Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 959
Table 189: Orchestra Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 960
Table 190: Oxford BioMedica’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 961
Table 191: OXiGENE’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 962
Table 192: PanaGin’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 963
Table 193: Pfizer’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 964
Table 194: Pharmaclon’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 970
Table 195: PharmaGap’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 971
Table 196: PharmaMar’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 972
Table 197: Pharmexa’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 973
Table 198: Philogen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 975
Table 199: Pierre Fabre’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 977
Table 200: Plexxikon’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 978
Table 201: POZEN’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 980
Table 202: Pro-Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 982
Table 203: Protherics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 984
Table 204: Receptor BioLogix’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 985
Table 205: Regeneron’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 986
Table 206: Rigel’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 987
Table 207: Sanofi-Aventis’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 989
Table 208: Santaris Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 990
Table 209: Sareum’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 991
Table 210: Shire’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 993
Table 211: Sigma-Tau’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 994
Table 212: Simcere Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 996
Table 213: Spirogen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 997
Table 214: SRI International’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 998
Table 215: SuperGen’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 999
Table 216: Supratek Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1001
Table 217: SynDevRx’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1003
Table 218: Synta Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1004
Table 219: Taiho’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1005
Table 220: Takeda’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1008
Table 221: Talon Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1010
Table 222: Targepeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1011
Table 223: Tau Therapeutics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1012
Table 224: Taxolog’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1014
Table 225: Telik’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1015
Table 226: Thallion Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1016
Table 227: The Genetics Company’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1017
Table 228: Therion Biologics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1019
Table 229: ThromboGenics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1021
Table 230: Titan Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1022
Table 231: TopoTarget’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1024
Table 232: Transgene’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1026
Table 233: Trion Pharma’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1027
Table 234: Vertex Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1028
Table 235: Vical’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1029
Table 236: VioQuest Pharmaceuticals’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1031
Table 237: Viralytics’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1033
Table 238: Wilex’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1034
Table 239: Wyeth’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1035
Table 240: Xerion’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1036
Table 241: Yakult Honsha’s Included Colorectal Cancer Pipeline and Competitive Fall-Out 1037
Table 242: YM BioSciences’ Included Colorectal Cancer Pipeline and Competitive Fall-Out 1039

This report includes 182 companies plus their collaborators:
Abbott
Adherex
Affimed Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Amgen
Anavex Life Sciences
Antisense Pharma
Apotex
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
AVEO
AVI BioPharma
Bayer
Betapharma
BioAlliance Pharma
Biocompatibles
Biogen Idec
BioNumerik
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cancer Advances
Cancer Research Technology
Can-Fite BioPharma
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
ChemGenex Pharmaceuticals
Choongwae
Circadian Technologies
Clavis Pharma
Cosmo Pharmaceuticals
CuraGen
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
Dendreon
Dynavax Technologies
EGEN Inc
Eisai
Eli Lilly
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Etubics
Exelixis
FasTrack Pharmaceuticals
Genmab
Genta
GenVec
Genzyme
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Gradalis
Green Cross
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IkerChem
Immunocore
Immunomedics
Incyte Corporation
InNexus Biotechnology
Inovio
Insys Therapeutics
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kiadis
Kyowa Hakko Kirin
Labopharm
Leo
Lorus Therapeutics
MacroGenics
Meda
MediGene
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Nektar Therapeutics
Nerviano Medical Sciences
NicOx
Nippon Kayaku
Novartis
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
Onconova
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Oxford BioMedica
OXiGENE
PanaGin
Pfizer
Pharmaclon
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Protherics
Receptor BioLogix
Regeneron
Rigel
Sanofi-Aventis
Santaris Pharma
Sareum
Shire
Sigma-Tau
Simcere Pharmaceuticals
Spirogen
SRI International
SuperGen
Supratek Pharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Telik
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
Vertex Pharmaceuticals
Vical
VioQuest Pharmaceuticals
Viralytics
Wilex
Wyeth
Xerion
Yakult Honsha
YM BioSciences
This report includes 347 cancer drugs. From Ceased to Marketed. Some examples are:
aderbasib
aflibercept
AMG-386
amrubicin hydrochloride
Angiozyme
ARQ-197
bevacizumab
brivanib alaninate
canfosfamide hydrochloride
capecitabine
catumaxomab
cediranib
celecoxib
cetuximab
cixutumumab
decitabine
denosumab
DI-17E6
doxifluridine
E-7820
entinostat
enzastaurin hydrochloride
everolimus
figitumumab
fosbretabulin tromethamine
I-131-labetuzumab
icotinib hydrochloride
icrucumab
imatinib mesilate
IMO-2055
interferon gamma
irinotecan bead
irinotecan hydrochloride
ispinesib mesylate
JX-594
mapatumumab
MDX-1106
MGN-1703
necitumumab
nimotuzumab
oblimersen sodium
Onyvax-105
panitumumab
pemetrexed disodium
perifosine
raltitrexed
ramucirumab
regorafenib
rilotumumab
robatumumab
STA-9090
sunitinib malate
tegafur + uracil
tegafur + uracil + leucovorin
tivozanib
trastuzumab
TS-1
varlitinib
veliparib

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market.
    To find out more about A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More


Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs. Learn More

Other selected research from the 'Oncology' category:


Prostate and Breast Cancer- New Treatments and Developmental Progress
Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. This report present the very latest on breast and prostate cancer drug development. Learn More


Triple Analysis: Leukemia, Lung Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More